S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58
S&P 500   3,900.79
DOW   31,253.13
QQQ   289.58

Hologic (HOLX) Stock Forecast, Price & News

+0.57 (+0.74%)
(As of 05/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
2.12 million shs
Average Volume
2.22 million shs
Market Capitalization
$19.48 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

Hologic logo

About Hologic

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.


See More Headlines

Industry, Sector and Symbol

X-ray apparatus & tubes
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$5.63 billion
Cash Flow
$10.29 per share
Book Value
$19.22 per share


Net Income
$1.87 billion
Pretax Margin




Free Float
Market Cap
$19.48 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

1.84 out of 5 stars

Medical Sector

491st out of 1,418 stocks

X-Ray Apparatus & Tubes Industry

3rd out of 6 stocks

Analyst Opinion: 1.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Hologic (NASDAQ:HOLX) Frequently Asked Questions

Is Hologic a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Hologic stock.
View analyst ratings for Hologic
or view top-rated stocks.

When is Hologic's next earnings date?

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Hologic

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) announced its quarterly earnings data on Wednesday, April, 27th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.55 by $0.52. The medical equipment provider had revenue of $1.44 billion for the quarter, compared to the consensus estimate of $1.28 billion. Hologic had a trailing twelve-month return on equity of 42.26% and a net margin of 28.79%. During the same period in the previous year, the business earned $2.59 earnings per share.
View Hologic's earnings history

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $5.45 to $5.65 for the period, compared to the consensus estimate of $5.13.

What price target have analysts set for HOLX?

9 Wall Street analysts have issued twelve-month price objectives for Hologic's stock. Their forecasts range from $75.00 to $95.00. On average, they expect Hologic's share price to reach $81.00 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts' price targets for Hologic
or view top-rated stocks among Wall Street analysts.

Who are Hologic's key executives?
Hologic's management team includes the following people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 58, Pay $4.51M) (LinkedIn Profile)
  • Ms. Karleen M. Oberton, Chief Financial Officer (Age 51, Pay $1.6M)
  • Mr. John M. Griffin, Gen. Counsel (Age 61, Pay $1.56M)
  • Mr. Sean S. Daugherty, Group Pres of Breast/Skeletal Health & GYN Surgical Solutions (Age 46, Pay $1.32M) (LinkedIn Profile)
  • Mr. Kevin R. Thornal, Division Pres of Diagnostic Solutions (Age 48, Pay $1.66M)
  • Ryan Simon, VP of Investor Relations
  • Ms. Elisabeth A. Hellmann, Sr. VP of Global HR & Corp. Communications (Age 53)
  • Mr. Jan Verstreken, Group Pres of International (Age 54)
  • Ms. Monica Aguirre Berthelot, VP & Chief of Staff
  • Mr. Mike Kelly, Chief Supply Chain Officer and Corp. VP of Quality Assurance & Regulatory Affairs
What is Steve MacMillan's approval rating as Hologic's CEO?

283 employees have rated Hologic CEO Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among Hologic's employees.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.18%), BlackRock Inc. (8.75%), State Street Corp (4.58%), Wellington Management Group LLP (1.86%), JPMorgan Chase & Co. (1.37%) and Northern Trust Corp (1.24%). Company insiders that own Hologic stock include Benjamin Jordan Cohn, Jan Verstreken, Kevin R Thornal, Peter J Valenti III, Sally Crawford, Sean S Daugherty and Sean S Daugherty.
View institutional ownership trends for Hologic

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., Caisse DE Depot ET Placement DU Quebec, Bellevue Group AG, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., Glenview Capital Management LLC, and Canada Pension Plan Investment Board. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Jan Verstreken, and Sean S Daugherty.
View insider buying and selling activity for Hologic
or view top insider-selling stocks.

Which major investors are buying Hologic stock?

HOLX stock was purchased by a variety of institutional investors in the last quarter, including Sound Shore Management Inc. CT, Arrowstreet Capital Limited Partnership, JPMorgan Chase & Co., Alyeska Investment Group L.P., Prudential Financial Inc., Renaissance Technologies LLC, American Century Companies Inc., and GW&K Investment Management LLC.
View insider buying and selling activity for Hologic
or or view top insider-buying stocks.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $78.12.

How much money does Hologic make?

Hologic has a market capitalization of $19.48 billion and generates $5.63 billion in revenue each year. The medical equipment provider earns $1.87 billion in net income (profit) each year or $6.069990 on an earnings per share basis.

How many employees does Hologic have?

Hologic employs 6,705 workers across the globe.

Does Hologic have any subsidiaries?

The following companies are subsidiares of Hologic: Focal Therapeutics.

When was Hologic founded?

Hologic was founded in 1985.

What is Hologic's official website?

The official website for Hologic is www.hologic.com.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at (508) 263-2900, via email at [email protected], or via fax at 781-890-8031.

This page was last updated on 5/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.